AveXis Inc. (NASDAQ:AVXS) was up 2.2% on Monday . The company traded as high as $36.45 and last traded at $35.70, with a volume of 83,264 shares changing hands. The stock had previously closed at $34.92.

A number of equities research analysts have recently weighed in on AVXS shares. Zacks Investment Research downgraded shares of AveXis from a “hold” rating to a “sell” rating in a research note on Wednesday, June 1st. Chardan Capital restated a “buy” rating and issued a $60.00 price target on shares of AveXis in a research note on Monday, May 9th. Goldman Sachs Group Inc. raised their price objective on shares of AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a report on Friday, May 13th. Wells Fargo & Co. started coverage on shares of AveXis in a report on Friday, July 15th. They issued a “market perform” rating for the company. Finally, Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating and raised their price objective for the company from $39.00 to $42.00 in a report on Wednesday, June 22nd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $43.80.

The firm’s market capitalization is $828.70 million. The stock’s 50-day moving average price is $40.36 and its 200 day moving average price is $30.55.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, May 12th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.89. Equities research analysts expect that AveXis Inc. will post ($3.90) earnings per share for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.